Corrigendum to Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to ConventionalDiuretics: aMulticentre, Double-blond, Parallel-group, Phase III study (Journal of International Medical Research, 40, 6, (2381-23930), 10.1177/030006051204000637);The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: A multicentre, double-blind, parallel-group, phase III study

Journal of International Medical Research

Volumn 40, Issue 6, 2012, Pages 2381-2393

  Sakaida, I ^a   Yanase, M ^b   Kobayashi, Y ^c   Yasutake, T ^d   Okada, M ^e   Okita, K ^f  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Takagi Hospital   (Japan)

^e OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^f Social Insurance Alliance Shimonoseki Kohsei Hospital   (Japan)

Author keywords

Aquaretic effect; Ascites; Diuretic; Liver cirrhosis; Pharmacodynamics; Pharmacokinetics; Tolvaptan

Indexed keywords

DIURETIC AGENT; ELECTROLYTE; TOLVAPTAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMAN; LABORATORY TEST; LIQUID CHROMATOGRAPHY; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SKIN EXFOLIATION; THIRST; TREATMENT RESPONSE; XEROSTOMIA;

EID: 84872245021     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513490097     Document Type: Erratum

References (31)

1. Verbeeck RK: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-1161.
2. Ginès P, Cárdenas A, Arroyo V, et al: Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654.
3. Runyon BA, for the AASLD Practice Guidelines Committee: Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107.
4. Wong F: Management of ascites in cirrhosis. J Gastroenterol Hepatol 2012; 27: 11-20.
5. Felker GM, Lee KL, Bull DA, et al: Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805.
6. Gross P: Treatment of hyponatremia. Intern Med 2008; 47: 885-891.
7. Butler J, Forman DE, Abraham WT, et al: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331-338.
8. Kuiper JJ, van Buuren HR, de Man RA: Ascites in cirrhosis: a review of management and complications. Neth J Med 2007; 65: 283-288.
9. Kuiper JJ, de Man RA, van Buuren HR: Review article: management of ascites and associated complications in patients with cirrhosis. Aliment Pharmacol Ther 2007; 26(suppl 2): 183-193.
10. Moore KP, Wong F, Gines P, et al: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-266.
11. Ireland R: Hyponatremia: prolonged use of the vasopressin antagonist tolvaptan is a safe and effective treatment for hyponatremia. Nat Rev Nephrol 2010; 6: 315.
12. Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008; 371: 1624-1632.
13. 2- receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-867.
14. 2 antagonist tolvaptan in rats with heart failure. Biochem Pharmacol 2007; 74: 1466-1475.
15. Gheorghiade M, Konstam MA, Burnett JC Jr, et al: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
16. Orlandi C, Zimmer CA, Gheorghiade M: Tolvaptan for the treatment of hyponatremia and congestive heart failure. Future Cardiol 2006; 2: 627-634.
17. Gheorghiade M, Orlandi C, Burnett JC, et al: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260-269.
18. Konstam MA, Gheorghiade M, Burnett JC Jr, et al: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
19. 2- receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
20. Okita K, Sakaida I, Okada M, et al: A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients withdecompensated liver cirrhosis. J Gastroenterol 2010; 45: 979-987.
21. 2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther 2011; 25(suppl 1): S5-S17.
22. Inomata T, Izumi T, Matsuzaki M, et al: Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25(suppl 1): S57-S65.
23. Saito H, Tada S, Nakamoto N, et al: Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol Res 2004; 29: 97-103.
24. Giordano S: The 2008 Declaration of Helsinki: some reflections. J Med Ethics 2010; 36: 598-603.
25. Pugh RN, Murray-Lyon IM, Dawson JL, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
26. del Olmo JA, Flor-Lorente B, Flor-Civera B, et al: Risk factors for nonhepatic surgery in patients with cirrhosis. World J Surg 2003; 27: 647-652.
27. Flear CT, Gill GV, Burn J: Hyponatraemia: mechanisms and management. Lancet 1981; 318: 26-31.
28. Miller M: Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc 2006; 54: 345-353.
29. Dixon MB, Lien YH: Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag 2008; 4: 1149-1155.
30. Vaghasiya RP, DeVita MV, Michelis MF: Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients. Int Urol Nephrol 2012; 44: 865-871.
31. Gassanov N, Semmo N, Semmo M, et al: Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol 2011; 67: 333-346.